Intermittent
fasting is associated with beneficial anthropometric and cardiometabolic
outcomes, according to a review just published online in JAMA Network Open.

Chanthawat
Patikorn, Pharm.D., from Chulalongkorn University in Bangkok, Thailand, and
colleagues conducted a systematic literature review to identify randomized
controlled trials that assessed the associations of intermittent fasting
(zero-calorie alternate-day fasting, modified alternate-day fasting, the 5:2
diet, and time-restricted eating) with obesity-related health outcomes.

Based on 130
identified studies, the researchers found that 28 of 104 associations were
statistically significant, and intermittent fasting showed beneficial outcomes
for body mass index, body weight, fat mass, low-density lipoprotein
cholesterol, total cholesterol, triglycerides, fasting plasma glucose, fasting
insulin, homeostatic model assessment of insulin resistance, and blood
pressure.

There was an
association observed between intermittent fasting and reduced fat-free mass.
High-quality evidence showed a significant association for modified
alternate-day fasting for one to two months and a moderate reduction in body
mass index among healthy adults and adults with overweight, obesity, or non-alcoholic
fatty liver disease.

“Our
results support the role of intermittent fasting, especially modified
alternate-day fasting, in adults with overweight or obesity as a weight loss
approach with metabolic benefits,” the authors wrote.

“More
clinical trials with long-term follow-up are needed to investigate the effects
of intermittent fasting on clinical outcomes such as cardiovascular events and
mortality.”

SOURCE: https://www.practiceupdate.com/C/129020/56?elsca1=emc_enews_topic-alert

REFERENCE: Patikorn
et al: Intermittent Fasting and Obesity-Related Health Outcomes; 
https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2787246?utm_campaign=articlePDF&utm_medium=articlePDFlink&utm_source=articlePDF&utm_content=jamanetworkopen.2021.39558